The evolution of the pharmaceutical-biotechnology industry
This paper presents an application of network economics to the formation of alliances in the biotechnology-pharmaceutical industry. The framework analysis provides insights under which firms create hybrid governance forms, integrate strategy and economics into a more holistic perspective on network strategy. Firm network types link network economies, competencies and market structure, creating integration between participants and change as additional dimensions. 'Change' introduces a dynamic, evolutionary aspect. The resulting contructs involve the network dimension as a mechanism design for investigating the evolution and life cycles of firm networks. An analysis of alliances within the pharmaceutical and biotechnology industries develops the framework, including a historical tracing, and an empirical examination of the relationship between collaboration rate (CR) and market performance of major globally operating pharmaceutical firms. Case examples, supported quantitatively and qualitatively, provide evidence for the efficacy and implications of the network dimension.
Volume (Year): 50 (2008)
Issue (Month): 5 ()
|Contact details of provider:|| Web page: http://www.tandfonline.com/FBSH20|
|Order Information:||Web: http://www.tandfonline.com/pricing/journal/FBSH20|
When requesting a correction, please mention this item's handle: RePEc:taf:bushst:v:50:y:2008:i:5:p:583-601. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Michael McNulty)
If references are entirely missing, you can add them using this form.